Kiniksa Pharmaceuticals International (KNSA) Competitors $28.09 -0.86 (-2.97%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$28.24 +0.15 (+0.52%) As of 07/11/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KNSA vs. VRNA, ROIV, ELAN, RVMD, LEGN, GRFS, TGTX, NUVL, LNTH, and TLXShould you be buying Kiniksa Pharmaceuticals International stock or one of its competitors? The main competitors of Kiniksa Pharmaceuticals International include Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), and Telix Pharmaceuticals (TLX). These companies are all part of the "pharmaceutical products" industry. Kiniksa Pharmaceuticals International vs. Its Competitors Verona Pharma PLC American Depositary Share Roivant Sciences Elanco Animal Health Revolution Medicines Legend Biotech Grifols TG Therapeutics Nuvalent Lantheus Telix Pharmaceuticals Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings. Which has more risk & volatility, VRNA or KNSA? Verona Pharma PLC American Depositary Share has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.05, meaning that its stock price is 95% less volatile than the S&P 500. Does the media prefer VRNA or KNSA? In the previous week, Verona Pharma PLC American Depositary Share had 41 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 46 mentions for Verona Pharma PLC American Depositary Share and 5 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.17 beat Verona Pharma PLC American Depositary Share's score of 0.53 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verona Pharma PLC American Depositary Share 17 Very Positive mention(s) 10 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kiniksa Pharmaceuticals International 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is VRNA or KNSA more profitable? Verona Pharma PLC American Depositary Share has a net margin of 0.00% compared to Kiniksa Pharmaceuticals International's net margin of -3.52%. Kiniksa Pharmaceuticals International's return on equity of -3.83% beat Verona Pharma PLC American Depositary Share's return on equity.Company Net Margins Return on Equity Return on Assets Verona Pharma PLC American Depositary ShareN/A -69.65% -28.00% Kiniksa Pharmaceuticals International -3.52%-3.83%-2.98% Do institutionals & insiders have more ownership in VRNA or KNSA? 85.9% of Verona Pharma PLC American Depositary Share shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 4.8% of Verona Pharma PLC American Depositary Share shares are held by company insiders. Comparatively, 53.5% of Kiniksa Pharmaceuticals International shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, VRNA or KNSA? Kiniksa Pharmaceuticals International has higher revenue and earnings than Verona Pharma PLC American Depositary Share. Kiniksa Pharmaceuticals International is trading at a lower price-to-earnings ratio than Verona Pharma PLC American Depositary Share, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerona Pharma PLC American Depositary Share$118.54M71.71-$173.42M-$2.00-52.42Kiniksa Pharmaceuticals International$423.24M4.84-$43.19M-$0.25-112.36 Do analysts rate VRNA or KNSA? Verona Pharma PLC American Depositary Share presently has a consensus target price of $107.45, suggesting a potential upside of 2.50%. Kiniksa Pharmaceuticals International has a consensus target price of $39.33, suggesting a potential upside of 40.03%. Given Kiniksa Pharmaceuticals International's stronger consensus rating and higher possible upside, analysts clearly believe Kiniksa Pharmaceuticals International is more favorable than Verona Pharma PLC American Depositary Share.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verona Pharma PLC American Depositary Share 0 Sell rating(s) 9 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.31Kiniksa Pharmaceuticals International 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryKiniksa Pharmaceuticals International beats Verona Pharma PLC American Depositary Share on 10 of the 16 factors compared between the two stocks. Get Kiniksa Pharmaceuticals International News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KNSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KNSA vs. The Competition Export to ExcelMetricKiniksa Pharmaceuticals InternationalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.05B$2.94B$5.56B$9.11BDividend YieldN/A2.42%5.06%4.01%P/E Ratio-112.3620.8528.2620.26Price / Sales4.84303.05437.10166.10Price / CashN/A42.1137.1257.67Price / Book4.267.638.045.49Net Income-$43.19M-$55.05M$3.19B$250.45M7 Day Performance0.84%8.43%3.62%4.79%1 Month Performance-0.74%8.14%5.98%9.59%1 Year Performance32.44%1.62%29.39%16.41% Kiniksa Pharmaceuticals International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KNSAKiniksa Pharmaceuticals International3.4055 of 5 stars$28.09-3.0%$39.33+40.0%+32.4%$2.05B$423.24M-112.36220Positive NewsAnalyst ForecastVRNAVerona Pharma PLC American Depositary Share2.3793 of 5 stars$91.20-0.4%$107.36+17.7%+403.5%$7.79B$42.28M-45.6030Trending NewsAnalyst ForecastROIVRoivant Sciences3.0006 of 5 stars$10.74-2.3%$17.50+62.9%+0.1%$7.47B$29.05M-42.96860News CoverageAnalyst UpgradeELANElanco Animal Health1.4963 of 5 stars$14.48-1.1%$15.33+5.9%+7.9%$7.27B$4.44B19.579,000News CoverageRVMDRevolution Medicines4.4905 of 5 stars$36.67-3.2%$67.58+84.3%-15.8%$7.05B$11.58M-9.17250LEGNLegend Biotech3.39 of 5 stars$35.87+0.6%$72.60+102.4%-28.3%$6.55B$627.24M-60.802,609Analyst ForecastGRFSGrifols3.5672 of 5 stars$8.87-2.3%$10.30+16.1%+17.9%$6.24B$7.81B7.5823,822News CoverageTGTXTG Therapeutics3.6936 of 5 stars$35.98-2.0%$40.80+13.4%+75.0%$5.83B$329M149.92290News CoveragePositive NewsAnalyst UpgradeNUVLNuvalent3.3693 of 5 stars$77.93-3.2%$119.60+53.5%+2.9%$5.78BN/A-17.7540Insider TradeLNTHLantheus4.5833 of 5 stars$79.19-1.5%$130.50+64.8%-34.1%$5.56B$1.53B22.50700News CoverageTLXTelix PharmaceuticalsN/A$15.48-3.7%$22.33+44.3%N/A$5.44B$516.72M0.00N/ANews CoverageAnalyst Forecast Related Companies and Tools Related Companies Verona Pharma PLC American Depositary Share Alternatives Roivant Sciences Alternatives Elanco Animal Health Alternatives Revolution Medicines Alternatives Legend Biotech Alternatives Grifols Alternatives TG Therapeutics Alternatives Nuvalent Alternatives Lantheus Alternatives Telix Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KNSA) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals International, plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KNSA Stock Alerts